The Middle East Respiratory Syndrome (MERS)

Infectious Disease Clinics of North America

Volumn 33, Issue 4, 2019, Pages 891-905

  Azhar, Esam I ^a   Hui, David S C ^b   Memish, Ziad A ^c,d   Drosten, Christian ^e   Zumla, Alimuddin ^f  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

^d Ministry of Health   (Saudi Arabia)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Epidemiology diagnosis; MERS CoV; Middle East respiratory syndrome coronavirus; Treatment

Indexed keywords

ALISPORIVIR; CHLOROQUINE; CYCLOSPORINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID; NELFINAVIR; NITAZOXANIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

CAMEL; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; INCUBATION TIME; INFECTION CONTROL; LABORATORY TEST; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY RATE; NONHUMAN; REVIEW; RISK FACTOR; ANIMAL; CORONAVIRUS INFECTION; GLOBAL HEALTH; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHYSIOLOGY; VIROLOGY; ZOONOSIS;

ANIMALS; CORONAVIRUS INFECTIONS; GLOBAL HEALTH; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RISK FACTORS; ZOONOSES;

EID: 85073813408     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2019.08.001     Document Type: Review

References (61)

1. WHO 2019.Middle East respiratory syndrome coronavirus (MERS-CoV. https://www.who.int/emergencies/mers-cov/en/
2. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995-1007.
3. Arabi YM, Balkhy HH, Hayden FG, Bouchama A,et al. Middle East Respiratory Syndrome. N Engl J Med. 2017 Feb 9;376(6):584-594.
4. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820.
5. WHO. List of priority Blueprint diseases. https://www.who.int/blueprint/priority-diseases/en/ -accessed January 20th 2019
6. Alanazi KH, Killerby ME, Biggs HM, et al. Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017. Infect Control Hosp Epidemiol. 2019 Jan;40(1):79-88
7. Oh MD, Choe PG, Oh HS, et al. Middle East Respiratory Syndrome Coronavirus Superspreading Event Involving 81 Persons, Korea 2015. J Korean Med Sci. 2015 Nov;30(11):1701-1705.
8. Oh MD, Park WB, Choe PG, et al. Viral Load Kinetics of MERS Coronavirus Infection. N Engl J Med. 2016;375(13):1303-1305.
9. Kang CK, Song KH, Choe PG, et al. Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea. J Korean Med Sci. 2017;32(5):744-749.
10. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018 Aug;18(8):e217-e227.
11. WHO. MERS Global summary and assessment of risk. https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf -accessed January 21st 2019.
12. Reusken CB, Haagmans BL, Muller MA, et al Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013 Oct;13(10):859-866
13. Reusken CB, Farag EA, Jonges M, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill. 2014;19(23). pii: 20829.
14. Drosten C, Kellam P, Memish ZA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014 Oct 2;371(14):1359-1360
15. Conzade R, Grant R, Malik MR, et al. Reported Direct and Indirect Contact with Dromedary Camels among Laboratory-Confirmed MERS-CoV Cases. Viruses. 2018 Aug 13;10(8). pii: E425. doi: 10.3390/v10080425.
16. van Doremalen N, Bushmaker T, Munster VJ. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill. 2013;18(38). pii: 20590.
17. Ommeh S, Zhang W, Zohaib A, et al. Genetic Evidence of Middle East Respiratory Syndrome Coronavirus (MERS-Cov) and Widespread Seroprevalence among Camels in Kenya. Virol Sin. 2018 Dec 20. doi: 10.1007/s12250-018-0076-4
18. Liljander A, Meyer B, Jores J, Muller MA, Lattwein E, Njeru I, Bett B, Drosten C, Corman VM. MERS-CoV Antibodies in Humans, Africa, 2013-2014. Emerg Infect Dis. 2016 Jun;22(6):1086-1089
19. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis. 2013;19(11):1819-1823.
20. Corman VM, Ithete NL, Richards LR, et al. Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol. 2014;88:11297-11303.
21. Sikkema RS, Farag EA, Himatt S, et al. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013-2014: A Case-Control Study. J Infect Dis. 2017;215(11):1702-1705.
22. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014; 370 (26):2499-2505
23. Memish ZA, Cotten M, Meyer B, et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis. 2014;20(6):1012-1015.
24. Al Hammadi ZM, Chu DK, Eltahir YM, et al. Asymptomatic MERS-CoV Infection in Humans Possibly Linked to Infected Dromedaries Imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis. 2015;21(12):2197-2200.
25. Arwady MA, Alraddadi B, Basler C, et al. Middle East Respiratory Syndrome Coronavirus Transmission in Extended Family, Saudi Arabia, 2014. Emerg Infect Dis. 2016;22(8):1395-1402.
26. Al-Abdallat MM, Payne DC, Alqasrawi S, et al.; Jordan MERS-CoV Investigation Team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225-1233.
27. Garbati MA, Fagbo SF, Fang VJ, et al. Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. PLoS One. 2016;11(11):e0165978.
28. Assiri A, McGeer A, Perl TM, et al; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407-416.
29. Arabi YM, Alomari A, MAndourah Y et al. Critically ill healthcare workers with the Middle East Respiratory Syndrome (MERS). Am J Critic Care Med. 2016:193:A6892
30. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018.15;197(6):757-767
31. Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis. 2017;17(1):615.
32. Yang YM, Hsu CY, Lai CC, et al. Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. Sci Rep 2017;7(1):11307.
33. Seys LJ, Widagdo W, Verhamme FM, et al. DPP4, the MERS coronavirus receptor, is upregulated in lungs of smokers and COPD patients. Clin Infect Dis. 2018 Jan 6;66(1):45-53
34. Zumla A, Hui DS. Infection control and MERS-CoV in health-care workers. Lancet. 2014 May 31;383(9932):1869-1871
35. WHO. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. Interim guidance January 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/178529/WHO_MERS_Clinical_15.1_eng.pdf;jsessionid=C30F5404588BE9AA533F2B350A0FED4C?sequence=1
36. World Health Organization. 2018. Laboratory testing for Middle East respiratory syndrome coronavirus. Interim guidance revised January 2018. Geneva (Switzerland): WHO Available at: https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1
37. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 2012;17:20334.
38. Corman VM, Albarrak AM, Omrani AS, et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. Clin Infect Dis. 2016;62(4):477-483.
39. Hashem AM, Al-Amri SS, Al-Subhi TL, et al. Development and validation of different indirect ELISAs for MERS-CoV serological testing. J Immunol Methods. 2019 Mar;466:41-46.
40. WHO. Laboratory biorisk management for laboratories handling human specimens suspected of confirmed to contain novel coronavirus: interim recommendations. https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1
41. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-347.
42. Chan JF, Yao Y, Yeung ML, et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015 Dec 15;212(12):1904-1913
43. Arabi YM, Deeb AM, Al-Hameed F, et al Macrolides in Critically Ill Patients with Middle East Respiratory Syndrome. Int J Infect Dis. 2019 Jan 25. pii: S1201-9712(19)30052-
44. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0
45. Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med. 2014 May;20(3):233-241
46. WHO. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection -Interim guidance. Available at: https://apps.who.int/iris/bitstream/handle/10665/174652/WHO_MERS_IPC_15.1_eng.pdf;jsessionid=F6766551B38E85D0DE2FBBDEB17A0892?sequence=1. Accessed September 14, 2019.
47. Kim SW, Park JW, Jung HD, et al. Risk factors for transmission of Middle East respiratory syndrome coronavirus infection during the 2015 outbreak in South Korea. Clin Infect Dis. 2017;64(5):551-557.
48. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 2015;6:269-278
49. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013 Jun 27;368(26):2487-2494
50. Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014 Aug 28;371(9):828-835
51. Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med. 2015;372(9):846-854.
52. Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis. 2013;17(9):e668-e672.
53. Siegel JD, Rhinehart E, Jackson M, et al. Health care infection control practices advisory committee. Am J Infect Control 2007;35(10 Suppl 2):S65-164.
54. MERS-CoV daily update. Saudi Arabia: Ministry of Health. Available at: https://www.moh.gov.sa/en/CCC/PressReleases/; http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html. Accessed July 31, 2019.
55. ISARIC and Public Health England. Treatment of MERS-CoV: Information for Clinicians. Clinical decision-making support for treatment of MERS-CoV patient. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360424/MERS_COV_information_for_clinicians_17_July.pdf
56. Schindewolf C, Menachery VD. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses. 2019 Jan 17;11(1). pii: E74. doi: 10.3390/v11010074
57. Memish ZA, Zumla A, Alhakeem RF, et al. Hajj: infectious disease surveillance and control. Lancet. 2014 Jun 14;383(9934):2073-2082.
58. Zumla A, Mwaba P, Bates M, Al-Tawfiq JA, Maeurer M, Memish ZA. The Hajj pilgrimage and surveillance for Middle East Respiratory syndrome coronavirus in pilgrims from African countries. Trop Med Int Health. 2014 Jul;19(7):838-840
59. Zumla A, Rustomjee R, Ntoumi F, et al. Middle East Respiratory Syndrome–need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa. Int J Infect Dis. 2015 Aug;37:77-79.
60. Hui DS, Perlman S, Zumla A. Spread of MERS to South Korea and China. Lancet Respir Med. 2015 Jul;3(7):509-510
61. FAO-OIE-WHO MERS Technical Working Group. MERS: Progress on the global response, remaining challenges and the way forward. Antiviral Res. 2018 Nov;159:35-44.